Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published online February 4, 2021]. CA Cancer J Clin, doi.org/10.3322/caac.21660

• PubMed
Sung H, Ferlay J, Siegel RL, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published online February 4, 2021]. CA Cancer J Clin, doi.org/10.3322/caac.21660)| false
• Export Citation

Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7–33.

• Crossref
• PubMed
Siegel RL, Miller KD, Fuchs HE, Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7–33.3343394610.3322/caac.21654)| false
• Search Google Scholar
• Export Citation

Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.

• Crossref
• PubMed
Berry DA, Cirrincione C, Henderson IC, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.1660908710.1001/jama.295.14.1658)| false
• Search Google Scholar
• Export Citation

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.

• Crossref
• PubMed
Paik S, Shak S, Tang G, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.1559133510.1056/NEJMoa041588)| false
• Search Google Scholar
• Export Citation

Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829–1834.

• Crossref
• PubMed
Dowsett M, Cuzick J, Wale C, Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829–1834.10.1200/JCO.2009.24.4798)| false
• Search Google Scholar
• Export Citation

Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677–1683.

• Crossref
• PubMed
Mamounas EP, Tang G, Fisher B, Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677–1683.2006518810.1200/JCO.2009.23.7610)| false
• Search Google Scholar
• Export Citation

Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.

• Crossref
• PubMed
Albain KS, Barlow WE, Shak S, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.2000517410.1016/S1470-2045(09)70314-6)| false
• Search Google Scholar
• Export Citation

Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.

• Crossref
• PubMed
Paik S, Tang G, Shak S, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.1672068010.1200/JCO.2005.04.7985)| false
• Search Google Scholar
• Export Citation

Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133–142.

• Crossref
• PubMed
Tang G, Shak S, Paik S, Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133–142.10.1007/s10549-010-1331-z21221771)| false
• Search Google Scholar
• Export Citation

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–121.

• Crossref
• PubMed
Sparano JA, Gray RJ, Makower DF, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–121.10.1056/NEJMoa180471029860917)| false
• Search Google Scholar
• Export Citation

Gluz O, Nitz UA, Christgen M, et al. West German Study Group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016;34:2341–2349.

• Crossref
• PubMed
Gluz O, Nitz UA, Christgen M, West German Study Group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016;34:2341–2349.10.1200/JCO.2015.63.5383)| false
• Search Google Scholar
• Export Citation

Cardoso F, van’t Veer LJ, Poncet C, et al. MINDACT: long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. Presented at the ASCO Virtual Scientific Program 2020; May 29–31, 2020. Abstract 506.

• PubMed
Cardoso F, van’t Veer LJ, Poncet C, MINDACT: long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. Presented at the ASCO Virtual Scientific Program 2020; May 29–31, 2020. Abstract 506.)| false
• Search Google Scholar
• Export Citation

Piccart M, van’t Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021;22:476–488.

• Crossref
• PubMed
Piccart M, van’t Veer LJ, Poncet C, 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021;22:476–488.10.1016/S1470-2045(21)00007-333721561)| false
• Search Google Scholar
• Export Citation

Kalinsky KB, Barlow WE, Meric-Bernstam F, et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/− chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Presented at the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8–11, 2020; San Antonio, Texas. Abstract GS3-00.

• PubMed
Kalinsky KB, Barlow WE, Meric-Bernstam F, et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/− chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Presented at the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8–11, 2020; San Antonio, Texas. Abstract GS3-00.)| false
• Export Citation

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst 2018;110:110.

• Crossref
• PubMed
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst 2018;110:110.10.1093/jnci/djx134)| false
• Search Google Scholar
• Export Citation

Noordhoek I, Treuner K, Putter H, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res 2021;27:311–319.

• Crossref
• PubMed
Noordhoek I, Treuner K, Putter H, Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR⁺ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res 2021;27:311–319.10.1158/1078-0432.CCR-20-273733109739)| false
• Search Google Scholar
• Export Citation

Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067–1076.

• Crossref
• PubMed
Sgroi DC, Sestak I, Cuzick J, Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067–1076.10.1016/S1470-2045(13)70387-524035531)| false
• Search Google Scholar
• Export Citation

Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol 2019;30:1776–1783.

• Crossref
• PubMed
Bartlett JMS, Sgroi DC, Treuner K, Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol 2019;30:1776–1783.10.1093/annonc/mdz28931504126)| false
• Search Google Scholar
• Export Citation

Sparano J, Gray RJ, Wood WC, et al. TAILORx: phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score [abstract]. J Clin Oncol 2018;36(Suppl):Abstract LBA1.

• Crossref
• PubMed
Sparano J, Gray RJ, Wood WC, TAILORx: phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score [abstract]. J Clin Oncol 2018;36(Suppl):Abstract LBA1.10.1200/JCO.2018.36.18_suppl.LBA1)| false
• Search Google Scholar
• Export Citation

Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122–137.

• Crossref
• PubMed
Francis PA, Pagani O, Fleming GF, Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122–137.10.1056/NEJMoa180316429863451)| false
• Search Google Scholar
• Export Citation